COXANTO

Product NDC
70512-814
11-digit product format
705120814
Labeler code
70512
Product ID
70512-814_419ad65e-5326-0755-e063-6394a90a7b2f
Type
HUMAN PRESCRIPTION DRUG
Nonproprietary name
oxaprozin
Dosage form
CAPSULE
Route
ORAL
Labeler
SOLA Pharmaceuticals, LLC
Application
NDA217927
Marketing category
NDA
Marketing start
2025-11-03
Substance
OXAPROZIN
Active strength
300 mg/1
Pharmacologic classes
Anti-Inflammatory Agents, Non-Steroidal [CS], Cyclooxygenase Inhibitors [MoA], Nonsteroidal Anti-inflammatory Drug [EPC]
NDC exclude flag
No
Listing certified through
2026-12-31
Current FDA listing
Yes

Source provenance: Browse the complete Orange Book source catalog · source snapshot 1.

Orange Book products#

Current product rows page 1 of 1 · 1 matching rows.

Application-product, Trade name, Ingredient table
Application-productTrade nameIngredientStrengthDosage form / routeTE codesRLD / RSApproval date
N217927-001COXANTOOXAPROZIN300MGCAPSULE / ORALRLD, RS2023-10-20

Observed Orange Book product history#

Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.

Captured, Edition, Application-product table
CapturedEditionApplication-productTrade nameStrengthDosage form / routeProduct TE source textRLD / RSApproval dateSource SHA-256
2026-02-19 14:30 UTC2026-02N217927-001COXANTO300MGCAPSULE / ORALRLD, RS2023-10-20011fe1cb6892…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12N217927-001COXANTO300MGCAPSULE / ORALRLD, RS2023-10-2031067a03dcf5…
2025-08-23 18:47 UTC2025-08N217927-001COXANTO300MGCAPSULE / ORALRLD, RS2023-10-206a471c1ec25d…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03N217927-001COXANTO300MGCAPSULE / ORALRLD, RS2023-10-20fd3edfee7708…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02N217927-001COXANTO300MGCAPSULE / ORALRLD, RS2023-10-20b8a1b40f171c…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01N217927-001COXANTO300MGCAPSULE / ORALRLD, RS2023-10-2003ed91905a0d…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12N217927-001COXANTO300MGCAPSULE / ORALRLD, RS2023-10-202680178bc6a6…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09N217927-001COXANTO300MGCAPSULE / ORALRLD, RS2023-10-205bbf6a4d5a75…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11N217927-001COXANTO300MGCAPSULE / ORALRLD, RS2023-10-20d8e5a09893c0…
2024-10-29 15:01 UTC2024-10N217927-001COXANTO300MGCAPSULE / ORALRLD, RS2023-10-20d06236e962d9…
2024-08-13 05:28 UTC · 3 captures of this ZIP2024-08N217927-001COXANTO300MGCAPSULE / ORALRLD, RS2023-10-2079d66fd596c7…
2024-07-13 05:37 UTC · 2 captures of this ZIP2024-07N217927-001COXANTO300MGCAPSULE / ORALRLD, RS2023-10-20301d65b070ca…
2024-06-18 03:08 UTC · 5 captures of this ZIP2024-06N217927-001COXANTO300MGCAPSULE / ORALRLD, RS2023-10-201e350fbaab3a…
2024-05-31 18:47 UTC2024-05N217927-001COXANTO300MGCAPSULE / ORALRLD, RS2023-10-208072bd15b7f6…
2024-03-16 18:09 UTC · 4 captures of this ZIP2024-03N217927-001COXANTO300MGCAPSULE / ORALRLD, RS2023-10-206a51e52b5d6a…
2024-02-18 07:12 UTC2024-02N217927-001COXANTO300MGCAPSULE / ORALRLD, RS2023-10-201c564ffb4f44…
2023-12-20 04:57 UTC2023-12N217927-001COXANTO300MGCAPSULE / ORALRLD, RS2023-10-20ea1830bbd6c7…
2023-11-28 05:40 UTC · 2 captures of this ZIP2023-11N217927-001COXANTO300MGCAPSULE / ORALRLD, RS2023-10-20a72a2bbeb626…
2026-07-26 02:55 UTC · 3 captures of this ZIP2026-06N217927-001COXANTO300MGCAPSULE / ORALRLD, RS2023-10-20a50c72e98297…

Additional Listing Data#

Finished product
Yes
Brand name base
COXANTO
Listing expiration
2026-12-31

Active Ingredients#

Ingredient, Strength table
IngredientStrength
OXAPROZIN300 mg/1

Harmonized UNII identifiers#

UNII identifiers page 1 of 1 · 1 matching rows.

Identifier, FDA.report destination table
IdentifierFDA.report destination
MHJ80W9LRBInternal UNII lookup

Harmonized RxCUI identifiers#

RxCUI identifiers page 1 of 1 · 2 matching rows.

Identifier, FDA.report destination table
IdentifierFDA.report destination
2668162Internal RxNorm lookup
2668168Internal RxNorm lookup

Harmonized SPL set identifiers#

SPL set identifiers page 1 of 1 · 1 matching rows.

Identifier, FDA.report destination table
IdentifierFDA.report destination
918127f0-9f2a-4edf-a2f7-07c01aa52bb5Available on FDA.report

DailyMed Product Concepts#

Product concept, Relation, Version table
Product conceptRelationVersionEffective
95b4bbb5-24e2-44a4-b351-d64e35d6e76aProduct name120250722
486cfca4-efa2-1446-eef2-3c74b667bb18Product name220170713

DailyMed Package Descriptions#

Package NDC, Product, Description table
Package NDCProductDescriptionFormQuantityStrengthSPL version
70512-814-60COXANTO60 in 1 BOTTLECAPSULE602

DailyMed Billing Units#

Package NDC, Billing unit, Product NDC table
Package NDCBilling unitProduct NDCDailyMed indexing SPLSPL versionEffective
70512-814-60EA - Each70512-814cb4cb14c-c894-49a5-8069-75b65a5c13db12025-12-16

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 2 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
OxaprozinOXAPROZINSOLA Pharmaceuticals, LLC450f5941-7f10-42fe-e063-6394a90a48032025-12-03Boxed warning, Warnings, Adverse reactionsExact identifier
application applno (NDA): 217927
application number: NDA217927
COXANTOOXAPROZINSOLA Pharmaceuticals, LLC918127f0-9f2a-4edf-a2f7-07c01aa52bb52025-10-20Boxed warning, Warnings, Adverse reactionsExact identifier
application applno (NDA): 217927
application number: NDA217927
ndc (product): 70512-814

DailyMed RxNorm Mappings#

RxCUI, RxNorm string, TTY table
RxCUIRxNorm stringTTYDailyMedSPL version
2668168COXANTO 300 MG Oral CapsulePSN918127f0-9f2a-4edf-a2f7-07c01aa52bb52
2668162oxaprozin 300 MG Oral CapsulePSN918127f0-9f2a-4edf-a2f7-07c01aa52bb52
2668168oxaprozin 300 MG Oral Capsule [Coxanto]SBD918127f0-9f2a-4edf-a2f7-07c01aa52bb52
2668162oxaprozin 300 MG Oral CapsuleSCD918127f0-9f2a-4edf-a2f7-07c01aa52bb52
2668168Coxanto 300 MG Oral CapsuleSY918127f0-9f2a-4edf-a2f7-07c01aa52bb52
2668162oxaprozin 300 MG Oral CapsuleSY918127f0-9f2a-4edf-a2f7-07c01aa52bb52

Packages#

Package NDC, 11-digit format, Description table
Package NDC11-digit formatDescriptionUnitsMarketing startSampleExclude flagStatus
70512-814-607051208146060 CAPSULE in 1 BOTTLE (70512-814-60) 60 capsule2025-11-03NoNoCurrent